Loading…
Regenerative Medicine Promotion Act of 2010
Legislative Progress
Introduced
September 22, 2010
Latest Action
September 22, 2010
Primary Sponsor
Michael CastleRepublican(DE)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 6,490 other HR bills in the 111th — cohort avg 44d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2010 · fourth_quarter · Health Issues
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Lobby in support of HR 6173. Advocate for new/modified regulations re: aprroval of regenerative medicine products. The Regenerative Medicine Promotion Act of 2010. Met with NIST to explore collaborations re: product standards
Client expense: Not reported · Firm income: $60,000
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE